Respective role of uraemic toxins and myeloperoxidase in the uraemic state.
BACKGROUND
In haemodialysis (HD) patients, advanced oxidation protein products (AOPP) were previously ascribed to oxidized plasma proteins, resulting mainly from increased myeloperoxidase (MPO) activity. The aim of the present study was to assess the mechanisms leading to the generation of AOPP during the course of chronic kidney disease including end-stage renal disease, with particular focus on AOPP and MPO characterization in the plasma at decreasing levels of kidney function.


METHODS
Phagocyte activation was evaluated by whole blood NADPH oxidase and MPO activities. In plasma, MPO protein concentration was quantified by ELISA and catalytic activity assayed by the spectrophotometric detection of phenol and 4-aminoantipyrine (AAP) co-oxidation in the presence of hydrogen peroxide (H(2)O(2)).


RESULTS
In HD patients, plasma AOPP concentration was linked to neutrophil oxidative activity. Such an association was not found in control subjects or predialysis patients, suggesting that in the latter, AOPP generation did not mainly result from MPO released by activated neutrophils. Similarly, plasma AOPP correlated with plasma MPO protein concentration in HD patients, but not in control subjects or predialysis patients, suggesting that in the latter AOPP did not predominantly result from MPO activity. This interpretation was supported by the observation of a greater degree of co-oxidation of phenol and AAP in the absence of H(2)O(2) in predialysis patients than in HD patients or control subjects. The contribution of MPO dramatically differed between predialysis and HD patients (2+/-5 vs 46+/-6%; P<0.001).


CONCLUSIONS
Our observations suggest that AOPP generation in predialysis patients mainly results from MPO-independent oxidation mechanisms.
Capeillère-Blandin
Chantal
C
Université Paris 5, CNRS UMR 8601, 45 rue des Saints Pères, 75270 Paris Cedex 06, France. Chantal.Capeillere-Blandin@univ-paris5.fr.
Gausson
Valérie
V
Nguyen
Anh Thu
AT
Descamps-Latscha
Béatrice
B
Drüeke
Tilman
T
Witko-Sarsat
Véronique
V
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007676:Kidney Failure, Chronic / Q000201:enzymology / Q000652:urine*; D008297:Male; D008875:Middle Aged; D010084:Oxidation-Reduction; D009195:Peroxidase / Q000378:metabolism / Q000502:physiology*; D010586:Phagocytes / Q000378:metabolism; D019800:Phenol / Q000378:metabolism; D011506:Proteins / Q000378:metabolism; D006435:Renal Dialysis; D014118:Toxins, Biological / Q000652:urine*; D014511:Uremia / Q000201:enzymology / Q000209:etiology*
D011506:Proteins; D014118:Toxins, Biological; D019800:Phenol; D009195:Peroxidase